Chimerna Therapeutics is pioneering a novel approach to RNA therapeutics through its Tornado technology, which focuses on the creation of stable circular RNAs. Traditional RNA therapies face significant challenges due to the inherent instability of linear RNAs, which are rapidly degraded by cellular enzymes. Chimerna's platform addresses this issue by enabling the production of circular RNAs that resist degradation, allowing for higher accumulation levels within cells. This stability is crucial for the therapeutic efficacy of RNA-based treatments, as it ensures that the RNAs can reach the necessary concentrations to effectively interact with disease-related proteins.

The Tornado technology not only enhances the stability of RNA but also allows for the genetic encoding of these circular RNAs within cells, effectively transforming them into drug-producing factories. By utilizing the cell's own machinery, Chimerna's approach involves the incorporation of self-cleaving ribozymes that facilitate the conversion of linear RNA into circular forms. This self-processing mechanism eliminates the need for additional enzymes, streamlining the production process. As a result, the circular RNAs generated through the Tornado platform are not only more stable but also more abundant than their linear counterparts, making them a promising solution for treating a variety of diseases, including neurodegenerative disorders and metabolic conditions.

United States

Chimerna Therapeutics is a biotech company focused on RNA therapeutics. Their platform for generating circular RNA overcomes the major limitations of RNA therapeutics, such as stability and abundance.

Chimerna Therapeutics

Company Details